Q2 FY26 · Ended Jun 30, 2026 · View SEC filing
Tax, not the business, pushed earnings down
Operating income rose 24.8%, yet net income fell 27.4% because the tax provision more than quadrupled.
For investorsWhat has to hold for earnings to track operating profit again
For foundersHow a device maker turns clinical trials into pricing power
Research rose 1.0% while sales rose 13.6%, so the wider margin came mostly from spending restraint, not cheaper production.
Still only 11.4% of sales, it gained share from both older lines, while aortic valves keep 72.3% of sales.
Hospitals pay for the outcome of a procedure, so making the valve costs a small share of its price.
Unlock the financial breakdown, competitive insights, historical trends and founder playbook, plus research across the company library.
Free CXProWealth membership required
Business Lens describes Edwards Lifesciences from its own filings with the SEC. It is not a view on its shares, a target, or advice to buy, sell or hold anything; figures are as filed and may be restated by the company later. The filing is linked above.
